CAMBRIDGE, Mass. - (Business Wire) Gloucester Pharmaceuticals today announced multiple presentations from clinical and preclinical studies of ISTODAX® (romidepsin) at the upcoming 51st American Society of Hematology (ASH) Annual Meeting being held in New Orleans, Louisiana, at the Ernest N. Morial Convention Center, December 5 – 8, 2009. ISTODAX, a novel histone deacetylase (HDAC) inhibitor, was recently approved by the U.S. Food and Drug Administration for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. Additionally, Gloucester is currently conducting a registration trial in peripheral T-cell lymphoma (PTCL) and studies of ISTODAX are being conducted in other hematologic and solid tumors. ISTODAX is not FDA approved for the treatment of PTCL or other indications. The schedule and abstract information for these presentations is as follows:
Saturday, December 5, 5:30 – 7:30 PM Central Time
- Publication # 1657 entitled “Final Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL)” presented by Richard Piekarz of the National Cancer Institute. Location: Hall E, Poster Board # I-679.
- Publication # 1689 entitled “The Combination of Romidepsin and Bortezomib Results in Synergistic Induction of Apoptosis in Human B-Lymphoma Cell Lines” presented by Seema S. Deshpande of Emory University School of Medicine. Location: Hall E, Poster Board # I-711.
Sunday, December 6, 6:00 – 8:00 PM Central Time
- Publication # 2683 entitled “Clinically Significant Responses Achieved with Romidepsin in 37 Patients with Cutaneous T-Cell Lymphoma (CTCL) with Blood Involvement” presented by Youn H. Kim of Stanford University. Location: Hall E, Poster Board # II-659.
- Publication # 3701 entitled “Characterization of Cyclic Hematologic Changes Observed in Patients with Cutaneous T-Cell Lymphoma (CTCL) Receiving Romidepsin, a Novel Histone Deacetylase (HDAC) Inhibitor” presented by Sean Whittaker of St. John's Institution of Dermatology, St. Thomas' Hospital. Location: Hall E, Poster Board # III-637.
Monday, December 7, 6:00 – 8:00 PM Central Time
- Publication # 3709 entitled “Systematic Assessment of Potential Cardiac Effects of the Novel Histone Deacetylase (HDAC) Inhibitor Romidepsin” presented by Christopher Cabell of Quintiles Transnational. Location: Hall E, Poster Board # III-645.
About ISTODAX®
ISTODAX, a novel histone deacetylase (HDAC) inhibitor, has been approved by the U.S. Food and Drug Administration for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. For full prescribing information, please visit www.ISTODAX.com. Gloucester is currently conducting a registration trial in peripheral T-cell lymphoma (PTCL) and additional studies of ISTODAX are being conducted in other hematologic and solid tumors. ISTODAX is not approved for the treatment of PTCL or other indications.
About Gloucester Pharmaceuticals
Gloucester Pharmaceuticals acquires clinical-stage oncology drug candidates and advances them through regulatory approval and commercialization. The Company’s first candidate, ISTODAX® (romidepsin), a novel histone deacetylase (HDAC) inhibitor, is FDA approved for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. Gloucester is currently conducting a registration trial in peripheral T-cell lymphoma (PTCL) and anticipates data from this study in 2010. In addition, the Company is continuing further investigation of ISTODAX in other hematologic indications and solid tumors. For more information, please visit www.gloucesterpharma.com.
MacDougall Biomedical Communications
Sarah Cavanaugh/Cory Tromblee, 781-235-3060
scavanaugh@macbiocom.com
ctromblee@macbiocom.com
